SHSüleyman Savaş Hacievliyagil

Süleyman Savaş Hacievliyagil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Süleyman Savaş Hacievliyagil has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2007
      • Vol. 55  (3) , 225-30

    [Value of plasma BNP levels as a prognostic marker in lung and heart disorders].

    by Ozkan Yetkin, Yüksel Aksoy, Hasan Turhan, Erdal In, Mukadder Karahan, Talat Kiliç, Süleyman Savaş Hacievliyagil, Hakan Günen

    In this study we included 155 subjects, 35 patients with left heart failure, 49 chronic obstructive pulmonary disease (COPD)-cor pulmonale, 26 COPD, 20 pulmonary embolism and 25 healthy subjects. Plasma BNP level in patient with left heart failure was significantly higher than COPD-cor pulmonale, COPD and control subject in respect 1167 +/- 746, 434 +/- 55, 32 +/- 36 and 32 +/- 12 pg/mL. Plasma BNP in group of cor pulmonale was higher than COPD and control subject 434 +/- 55 vs. 32 +/- 12 pg/mL. There were no difference between COPD and control subject 32 +/- 36 vs. 32 +/- 12 pg/mL. In pulmonary embolism BNP was higher than controls 357 +/- 391 vs. 32 +/- 12 pg/mL and BNP levels of massive pulmonary embolism was higher non-massive embolism 699 +/- 394 vs 166 +/- 213 pg/mL. In this study BNP levels negative correlated with EF and positive correlated with pulmonary artery pressure. We suggest that increased BNP levels are correlated with ventricular failure and BNP is diagnostic and prognostic marker of heart failure and increased right ventricular pressure contributes to elevated BNP in patients with PE.


  • Prevalence and clinical significance of a patent foramen ovale in patients with chronic obstructive pulmonary disease

    by Suleyman Savas Hacievliyagil, Hakan Gunen, Feridun M. Kosar, Ibrahim Sahin, Talat Kilic


    • 1 January 2004
      • Vol. 52  (1) , 86-94

    [Acute oxygen treatment].

    by Ozkan Kizkin, Süleyman Savaş Hacievliyagil, Hakan Günen

    Oxygen treatment is commonly used in clinical practice. Although this treatment was taught during medical education under different titles, it is observed that doctors do not administer oxygen treatment in adequate periods and doses. The possible cause of this may be that oxygen is not considered as a drug. The results of inadequate dose and insufficient monitoring in oxygen treatment would be serious. On the other hand, failure to correct hypoxaemia fearing from hypoventilation and carbon dioxide retention is not acceptable. For a safe oxygen treatment, doctor must know its indications, oxygen delivery systems, flow rates and monitoring. The aim of this review is to refresh our knowledge about when, how and how much to start oxygen treatment and how to monitor it.